Adenylate kinase immobilized on graphene oxide impairs progression of human lung carcinoma epithelial cells through adenosinergic pathway
Source abstract
Abstract
Abstract Purinergic signaling, the oldest evolutionary transmitter system, has been increasingly studied as a pivotal target for novel anti‐cancer therapies. In the present work, the developed nanobiocatalytic system consisting of adenylate kinase immobilized on graphene oxide (AK‐GO) was characterized in terms of its physicochemical and biochemical properties. We put special emphasis on the AK‐GO influence on purinergic signaling components, that is, ecto‐nucleotides concentration and ecto‐enzymes expression and activity in human lung carcinoma epithelial (A549) cells. The immobilization‐dependent modification of AK kinetic parameters allowed for the removal of ATP excess while maintaining low ATP concentrations, efficient decrease in adenosine concentration, and control of the nucleotide balance in carcinoma cells. The cyto‐ and hemocompatibility of developed AK‐GO nanobiocatalytic system indicates that it can be successfully harnessed for biomedical applications. In A549 cells treated with AK‐GO nanobiocatalytic system, the significantly decreased adenosinergic signaling results in reduction of the proliferation and migration capability of cancer cells. This finding is particularly relevant in regard to AK‐GO prospective anti‐cancer applications.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Collaboration in agile enterprises · Advanced Manufacturing and Logistics Optimization · Digital Transformation in Industry
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biochemistry, Faculty of Biological and Veterinary Sciences Nicolaus Copernicus University in Torun Torun Poland
Department of Physical Chemistry, Faculty of Pharmacy Medical University of Bialystok Bialystok Poland
Department of Materials Chemistry, Adsorption and Catalysis, Faculty of Chemistry Nicolaus Copernicus University in Torun Torun Poland
Department of Medicinal Chemistry, Collegium Medicum in Bydgoszcz, Faculty of Pharmacy Nicolaus Copernicus University in Torun Bydgoszcz Poland
References (48)
Show source-provided references
1. 10.1039/C5NR00438A10.1039/C5NR00438A ↗
2. 10.1007/s00114-017-1459-310.1007/s00114-017-1459-3 ↗
3. 10.1016/j.msec.2018.03.00610.1016/j.msec.2018.03.006 ↗
4. 10.1002/adhm.20160074510.1002/adhm.201600745 ↗
5. 10.1002/adhm.20200176110.1002/adhm.202001761 ↗
6. 10.1016/j.cbi.2023.11044410.1016/j.cbi.2023.110444 ↗
7. 10.1124/pr.58.1.510.1124/pr.58.1.5 ↗
8. 10.1007/s11302-012-9309-410.1007/s11302-012-9309-4 ↗
9. 10.3109/10409238.2014.95362710.3109/10409238.2014.953627 ↗
10. 10.1038/s41392‐021‐00553‐z10.1038/s41392‐021‐00553‐z ↗
11. 10.3389/fphar.2020.0079310.3389/fphar.2020.00793 ↗
12. 10.1038/s41568‐018‐0037‐010.1038/s41568‐018‐0037‐0 ↗
13. 10.1124/pharmrev.121.00052810.1124/pharmrev.121.000528 ↗
14. 10.1007/978‐94‐007‐4719‐7_210.1007/978‐94‐007‐4719‐7_2 ↗
15. 10.1007/s11302-018-9641-410.1007/s11302-018-9641-4 ↗
16. 10.1016/j.ccell.2019.10.00710.1016/j.ccell.2019.10.007 ↗
17. 10.1016/S0163-7258(00)00053-X10.1016/S0163-7258(00)00053-X ↗
18. 10.4110/in.2019.19.e2310.4110/in.2019.19.e23 ↗
19. 10.1007/s00280‐020‐04077‐110.1007/s00280‐020‐04077‐1 ↗
20. 10.1007/s12035-019-01730-610.1007/s12035-019-01730-6 ↗
21. 10.3389/fnins.2021.64847610.3389/fnins.2021.648476 ↗
22. 10.1039/C6RA03189G10.1039/C6RA03189G ↗
23. 10.1021/acs.jpcb.1c0829410.1021/acs.jpcb.1c08294 ↗
24. 10.1016/j.jchromb.2005.05.02610.1016/j.jchromb.2005.05.026 ↗
25. 10.1093/clinchem/38.1.13210.1093/clinchem/38.1.132 ↗
26. 10.1016/j.biotechadv.2021.10782110.1016/j.biotechadv.2021.107821 ↗
27. 10.3390/ijms1912383710.3390/ijms19123837 ↗
28. 10.1002/jcb.2566410.1002/jcb.25664 ↗
29. 10.1016/j.ijbiomac.2021.06.07310.1016/j.ijbiomac.2021.06.073 ↗
30. 10.1016/bs.mie.2018.06.01010.1016/bs.mie.2018.06.010 ↗
31. 10.1016/j.ijbiomac.2018.01.17310.1016/j.ijbiomac.2018.01.173 ↗
32. 10.1039/C6SM02179D10.1039/C6SM02179D ↗
33. 10.1039/C5RA24637G10.1039/C5RA24637G ↗
34. 10.1016/j.ijbiomac.2021.03.01610.1016/j.ijbiomac.2021.03.016 ↗
35. 10.1557/jmr.2017.38810.1557/jmr.2017.388 ↗
36. 10.1007/s11356-017-9788-510.1007/s11356-017-9788-5 ↗
37. 10.1039/C8NA00178B10.1039/C8NA00178B ↗
38. 10.1039/C6RA13607A10.1039/C6RA13607A ↗
39. 10.1021/am200428v10.1021/am200428v ↗
40. 10.3390/ijms2215813610.3390/ijms22158136 ↗
41. 10.1158/1541-7786.MCR-16-011810.1158/1541-7786.MCR-16-0118 ↗
42. 10.1007/s11302-014-9411-x10.1007/s11302-014-9411-x ↗
43. 10.3390/ijms2309512610.3390/ijms23095126 ↗
44. 10.1158/0008-5472.CAN-16-054410.1158/0008-5472.CAN-16-0544 ↗
45. 10.1073/pnas.180969511510.1073/pnas.1809695115 ↗
46. 10.7150/thno.7058110.7150/thno.70581 ↗
47. 10.18632/oncotarget.1443410.18632/oncotarget.14434 ↗
48. 10.3389/fimmu.2019.0163310.3389/fimmu.2019.01633 ↗